What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Gary S. Hoffman mostly deals with Surgery, Internal medicine, Vasculitis, Gastroenterology and Systemic disease.
His Surgery research includes elements of Wegener s, Pharmacotherapy and Giant cell arteritis.
His Vasculitis study combines topics from a wide range of disciplines, such as Exacerbation, Immunology, Asymptomatic, Matrigel and Cohort.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Infliximab and Chemotherapy.
His Systemic disease study integrates concerns from other disciplines, such as Bladder cancer, Urinary bladder, Vascular disease and Cystoscopy.
Gary S. Hoffman studied Prednisone and Granulomatosis with polyangiitis that intersect with Family medicine and Rheumatism.
His most cited work include:
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (2901 citations)
- Wegener granulomatosis : an analysis of 158 patients (2112 citations)
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (1616 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Vasculitis, Internal medicine, Immunology, Pathology and Surgery.
He interconnects Systemic disease and Dermatology in the investigation of issues within Vasculitis.
His biological study spans a wide range of topics, including Gastroenterology and Rituximab.
Gary S. Hoffman works mostly in the field of Immunology, limiting it down to concerns involving Anti-neutrophil cytoplasmic antibody and, occasionally, Proteinase 3.
Gary S. Hoffman is interested in Prednisone, which is a field of Surgery.
His Granulomatosis with polyangiitis research is multidisciplinary, relying on both Microscopic polyangiitis and Eosinophilic.
He most often published in these fields:
- Vasculitis (40.24%)
- Internal medicine (32.32%)
- Immunology (27.13%)
What were the highlights of his more recent work (between 2013-2021)?
- Vasculitis (40.24%)
- Internal medicine (32.32%)
- Granulomatosis with polyangiitis (17.68%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Vasculitis, Internal medicine, Granulomatosis with polyangiitis, Immunology and Gastroenterology.
His Vasculitis research is multidisciplinary, incorporating perspectives in Maintenance therapy and Rituximab.
His work in the fields of Azathioprine, Cohort, Birmingham Vasculitis Activity Score and Retrospective cohort study overlaps with other areas such as Univariate analysis.
His Granulomatosis with polyangiitis research integrates issues from Surgery, Microscopic polyangiitis, Eosinophilic, Etanercept and Craniofacial.
His studies deal with areas such as Biomarker, Genetics and Genome-wide association study as well as Immunology.
His research in Gastroenterology intersects with topics in Urinary system, Systemic vasculitis and Hazard ratio.
Between 2013 and 2021, his most popular works were:
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. (163 citations)
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type (113 citations)
- A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. (93 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
